ECTRIMS: Novel MS Drug Efficacy, Safety Last (CME/CE)

AMSTERDAM (MedPage Today) — The investigational oral drug teriflunomide (Aubagio) seems to have maintained its effectiveness during up to nine years of follow-up in clinical trial patients with the relapsing form of multiple sclerosis, and no late safety problems have been noticed, researchers said here.

http://www.medpagetoday.com/MeetingCoverage/ECTRIMS/29299

Sent with MobileRSS for iPhone

Júlio Leonardo B. Pereira
http://lattes.cnpq.br/7687651239699170
http://www.neurocirurgiabr.orghttp://www.neurocancer.com

neurocirurgiabr

Neurosurgery from Brazil.To provide neurosurgeouns with the most timely comprehensive and relevant clinical information to improve patient care; we offer a web site where patients can view our patient-level information for free

You may also like...

Leave a Reply

%d bloggers like this: